Acute respiratory distress syndrome (ARDS) remains one of the deadliest complications of severe infections, sepsis, trauma, ...

CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring ...

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ...

Researchers at Oregon Health and Science University have identified ferroptosis, an iron-driven form of cell death, in ...

US FDA approves Pfizer & Astellas’ Padcev plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of cisplatin eligibility: New York Monday, July 13, 2026, 13:00 ...

The epigenetic modifier MLL4 has an unassuming name—the 4, for instance, indicates it's just one in a family of such ...

Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers due to its aggressive biology and ...

(Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross ...

FDA Drug Approvals and Regulatory Updates The table below is a review of notable updates that occurred in June 2026 for investigational products in development (not an inclusive list). Click on the ...

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein C-III-directed antisense oligonucleotide ...

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, ...